Dexamethasone (DEX) has been widely used to treat a variety of diseases, including
autoimmune diseases, allergies, ocular disorders, cancer, and, more recently, COVID-19 …

Simple Summary During the last two decades, collaborative translational studies utilizing
novel methodologies have dramatically advanced our understanding of multiple myeloma …

Despite the tremendous advances in the treatment of multiple myeloma, mortality remains
significant, highlighting the need for new effective strategies. In recent years, daratumumab …

Ligation of the inhibitory receptor NKG2A by its ligand HLA-E negatively regulates the
activation of natural killer (NK) cells, as well as subsets of CD8+ T cells and innate T cell …

Simple Summary As convergence points of signaling cascades, transcription factors (TFs)
play a crucial role in cell physiology, including B cell differentiation, and are deregulated in …

Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …

Immunomodulatory imide drugs (IMiDs), proteasome inhibitors (PIs) and anti‐CD38
monoclonal antibodies (MoAbs) are the pillars of modern multiple myeloma (MM) therapy …

Background Selinexor 80 mg combined with low-dose dexamethasone (Sd) demonstrated
significant clinical benefit in patients with relapsed/refractory multiple myeloma (RRMM) who …

Therapy for multiple myeloma (MM), a hematologic neoplasm of plasma cells, has
undergone remarkable changes over the past 25 years. Small molecules (molecular weight …

Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus
dexamethasone was approved in Europe for use in patients with triple-class refractory …